MedTrace Logo

NMBA Reversal and Postoperative Urinary Retention

NCT06948409 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70000

Last updated 2026-01-23

No results posted yet for this study

Summary

In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.

Conditions

  • Neuromuscular Blocking Agents
  • Urinary Retention After Procedure
  • Urinary Retention Postoperative
  • Neuromuscular Blockade Reversal Agent
  • Neuromuscular Blockade
  • Costs
  • Atropine
  • Sugammadex
  • Glycopyrrolate
  • Neostigmine
  • Anesthesia

Interventions

DRUG

Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])

The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.

Sponsors & Collaborators

Principal Investigators

  • Maximilian S Schaefer, MD, PhD · Center for Anesthesia Research Excellence, Beth Israel Deaconess Medical Center

  • Luca J Wachtendorf, MD · Center for Anesthesia Research Excellence, Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-08
Primary Completion
2025-08-31
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06948409 on ClinicalTrials.gov